MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ
1.890
-0.110
-5.50%
After Hours: 1.760 -0.13 -6.88% 19:44 05/13 EDT
OPEN
1.970
PREV CLOSE
2.000
HIGH
2.030
LOW
1.710
VOLUME
3.88M
TURNOVER
--
52 WEEK HIGH
20.28
52 WEEK LOW
1.710
MARKET CAP
3.34M
P/E (TTM)
-0.2817
1D
5D
1M
3M
1Y
5Y
1D
RedHill Biopharma Secures Asset Freeze in Legal Victory Over Kukbo
TipRanks · 12h ago
RedHill Biopharma secures Kukbo asset freeze after $8.25M favorable court ruling
TipRanks · 13h ago
RedHill Biopharma Secures South Korean Court Approval For Asset Attachment Following $8.25M Judgment Against Kukbo
Benzinga · 13h ago
Weekly Report: what happened at RDHL last week (0505-0509)?
Weekly Report · 1d ago
RedHill Biopharma Postpones Annual Shareholders Meeting Due to Lack of Quorum
TipRanks · 05/05 12:29
Weekly Report: what happened at RDHL last week (0428-0502)?
Weekly Report · 05/05 10:24
RedHill Biopharma Launches H. Pylori Education Program at Gastroenterology Congress
TipRanks · 05/02 11:27
RedHill Biopharma Secures Key Chinese Patent for COVID-19 Treatment RHB-107
TipRanks · 04/28 11:27
More
About RDHL
More
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Recently
Symbol
Price
%Change

Webull offers RedHill Biopharma Ltd (ADR) stock information, including NASDAQ: RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.